NewLimit
PrivateLast Round
Series C
Jun 2, 2026
Est. Valuation
$3.1B
Total Funding Raised
$760M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
NewLimit is a biotechnology company that develops epigenetic reprogramming therapies to reverse the aging process and extend human healthspan.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
NewLimit Comparables
Compare NewLimit with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Retro Biosciences | 88% | |
| Altos Labs | 86% | |
| Life Biosciences | 80% |
NewLimit Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Jun 2, 2026 | ||||
| Convertible Debt | Oct 20, 2025 | ||||
| Series B | May 6, 2025 | ||||
| Series A | May 16, 2023 |
NewLimit Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Human Capital | Convertible Debt, Series C, Series B |
| S32 | Convertible Debt |
| Duke University Management Company | Convertible Debt |
| Greenoaks Capital Partners | Series C |
| Khosla Ventures | Series C, Series B |
| Founders Fund | Series B, Series C, Series A |
| Thrive Capital | Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 15, 2026
Grew 21% QoQ, from 52 to 63 employees.
- Jul 26, 2026
Monthly visitors grew 340% MoM, reaching 28.7K.
Recent news
Latest coverage and updates
- recognized_asSep 25, 2026
NewLimit recognized as Endpoints 11 2026 winner.
NewLimit Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about NewLimit's valuation, stock price, and market status.
Is NewLimit a public or private company?
NewLimit is a private company.
What is the current stock price of NewLimit?
NewLimit is a private company with no public stock price. No recent secondary market data is available.
How much is NewLimit worth (valuation)?
NewLimit's valuation is estimated at $3.1B based on funding round data.
Can I buy NewLimit stock?
NewLimit shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was NewLimit's last funding round?
NewLimit's most recent funding round was Series C on June 2, 2026.
Who are the main investors in NewLimit?
Key investors in NewLimit include Founders Fund, Kleiner Perkins, Dimension Capital.
Will NewLimit IPO soon?
No public IPO plans have been announced for NewLimit.
How can I track NewLimit secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor NewLimit's secondary market activity and sign up for updates.